AcquisitionsJun 9, 2026, 06:07 AM
Novanta to Acquire Riverpoint Medical for $1.2B Plus Milestone
AI Summary
Novanta Inc. announced a definitive agreement to acquire Riverpoint Medical for $1.2 billion in cash plus a $250 million milestone payment. This strategic acquisition aims to accelerate Novanta's growth, expand its portfolio into the high-growth minimally invasive surgery segment, and double its recurring medical consumables revenue. The transaction is expected to be immediately accretive to Novanta's financial performance and is anticipated to close in the third quarter of 2026, subject to customary regulatory approvals and closing conditions. The deal will be financed through a combination of cash on hand, existing credit facilities, and a recent equity raise.
Key Highlights
- Novanta Inc. to acquire Riverpoint Medical for $1.2 billion cash upfront and $250 million milestone payment.
- Transaction is expected to close in Q3 2026, subject to regulatory approvals.
- Acquisition accelerates Novanta's strategy, expands portfolio into minimally invasive surgery.
- Riverpoint Medical is a leader in high-growth minimally invasive surgical consumables.
- The deal is expected to be immediately accretive to Novanta's revenue growth, margins, EPS, and cash flows.
- Novanta's medical consumables revenue is projected to double to approximately $300 million post-acquisition.
- Financing includes cash on hand, existing credit facility, and a recent $300 million equity raise.
- Novanta's net leverage ratio expected to be ~2.7x at close, below 2.3x by year-end 2027.
Price Impact
More from NOVT